Arcturus Therapeutics
ARCT
20 hedge funds and large institutions have $52.2M invested in Arcturus Therapeutics in 2013 Q4 according to their latest regulatory filings, with 10 funds opening new positions, 7 increasing their positions, 2 reducing their positions, and 1 closing their positions.
900% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 1
250% more repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 2
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
82% more funds holding
Funds holding: 11 → 20 (+9)
65% more capital invested
Capital invested by funds: $31.6M → $52.2M (+$20.6M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
JP Morgan Chase
New York
|
+$5.39M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$4.49M |
| 3 |
SC
Sophrosyne Capital
New York
|
+$3.67M |
| 4 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.27M |
| 5 |
KCM
Knoll Capital Management
Miami,
Florida
|
+$1.8M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Acadian Asset Management
Boston,
Massachusetts
|
-$36.7K |
| 2 |
PCM
Prelude Capital Management
New York
|
-$25K |
| 3 |
TMC
Trellus Management Company
Delray Beach,
Florida
|
-$18K |
ARCT Hedge Fund Activity: Q4 2013 in Review
20 of the 3,459 institutional investors tracked by Wall St. Rank reported a position in Arcturus Therapeutics (ARCT) for Q4 2013, worth a combined $52.2M — up 65% from $31.6M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new ARCT positions and 1 closed out — a net gain of 9 holders — while 7 added to existing stakes and 2 trimmed.
The largest buyer was JP Morgan Chase, adding an estimated $5.39M. The largest seller was Acadian Asset Management, cutting an estimated $36.7K.
- 20 institutional investors held Arcturus Therapeutics (ARCT) as of Q4 2013, up from 11 in Q3 2013.
- Funds reported $52.2M of Arcturus Therapeutics stock for Q4 2013, up 65% quarter-over-quarter.
- 10 funds opened new Arcturus Therapeutics positions in Q4 2013 and 1 closed out, a net change of +9 holders.
- The largest Arcturus Therapeutics buyer in Q4 2013 was JP Morgan Chase, an estimated $5.39M added.
- The largest Arcturus Therapeutics seller in Q4 2013 was Acadian Asset Management, an estimated $36.7K sold.
Based on aggregated 13F filings for Q4 2013.